Nasdaq exas.
The public float for EXAS is 179.16M, and currently, short sellers hold a 4.07% ratio of that floaft. The average trading volume of EXAS on November 30, 2023 was 1.42M shares. EXAS) stock’s latest price update. Exact Sciences Corp. (NASDAQ: EXAS)’s stock price has increased by 0.14 compared to its previous closing price of 64.97.
TSLA. Tesla, Inc. Common Stock. $207.30 +1.54 +0.75%. Find the latest dividend history for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.The Zacks Consensus Estimate for Exact Sciences’ third-quarter 2023 revenues is pegged at $614.6 million, suggesting a rise of 17.5% from the year-ago reported figure.Shares of Exact Sciences ( EXAS 4.73%) stormed higher by 16.5% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain ...The Zacks Consensus Estimate for Exact Sciences’ third-quarter 2023 revenues is pegged at $614.6 million, suggesting a rise of 17.5% from the year-ago reported figure.MADISON, Wis., Jan. 5, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has completed its previously announced acquisition of Thrive Earlier Detection Corp. ("Thrive").
Board. Exact Sciences schedules third quarter 2023 earnings call. October 09 2023 - 06:00AM. PR Newswire (US) MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a ...
Sep 9, 2023 · Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ...
May 15, 2023 · Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The company is known for its flagship colon cancer ... MADISON, Wis., Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23 ...Exact Sciences was founded in 1995 in Marlborough, Massachusetts, by Stanley Lapidus and Anthony Shuber as a company focused on the development of a non-invasive test for colorectal cancer. The company eventually went public with an initial offering on the NASDAQ in 2001. Exact Sciences Corporation Common Stock (EXAS) Advanced Charting - Nasdaq offers advanced charting & market activity data for US and global markets.EXAS NASDAQ. EXAS NASDAQ. EXAS NASDAQ. Market closed Market closed. 67.03 USD R +3.03 +4.73%. At close at Dec 1, 16:58 UTC-8. USD. No trades. See on …Web
MADISON, Wis., Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23 ...
Exact Sciences Corporation EXAS recently presented modeling data that shows Cologuard (mt-sDNA) as the most cost-effective colorectal cancer (CRC) detection and screening option at the 2021 ...
Exact Sciences's earnings have been declining at an average annual rate of -21.7%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 28.7% per year. This section of the company report contains some beta features. How Exact Sciences makes and spends money.EXAS earnings call for the period ending March 31, 2023. Image source: The Motley Fool. Exact Sciences ( EXAS 0.14% ) Q1 2023 Earnings Call May 09, 2023 , 5:00 p.m. ETA market research report on Exact Sciences ( NASDAQ: EXAS) from Cathie Wood's ARK-Invest ( ARKK) ( ARKG) has caught a lot of attention with another assertive call on the share price performance in ...One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -4.51%, and its shares gained 38.05% of their value over the last 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a market ...Exact Sciences (NASDAQ: EXAS) Stock Quote. Follow Insider Trades Visit website. Last Trade: US$64.00 -1.06 -1.63. Volume: 1,800,029. 5-Day Change: -1.75%. YTD ...
MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its ...Webull offers EXAS Ent Holdg (EXAS) historical stock prices, in-depth market analysis, NASDAQ: EXAS real-time stock quote data, in-depth charts, free EXAS options chain data, and a fully built financial calendar to help you invest smart. Buy EXAS stock at Webull.EXACT Sciences Corporation stock price live 67.03, this page displays NASDAQ EXAS stock exchange data. View the EXAS premarket stock price ahead of the market session or assess the after hours quote.Jul 31, 2023 · EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ... In the past 30 days, the Zacks Consensus Estimate for Exact Sciences’ loss for 2023 has remained constant at $1.90 per share. The Zacks Consensus Estimate for 2023 revenues is pegged at $2.46 ...The Zacks Consensus Estimate for Exact Sciences’ third-quarter 2023 revenues is pegged at $614.6 million, suggesting a rise of 17.5% from the year-ago reported figure.In the past 30 days, the Zacks Consensus Estimate for Exact Sciences’ loss for 2023 has remained constant at $1.90 per share. The Zacks Consensus Estimate for 2023 revenues is pegged at $2.46 ...
In trading on Thursday, shares of EXACT Sciences Corp. (Symbol: EXAS) crossed below their 200 day moving average of $123.15, changing hands as low as $122.60 per share. EXACT Sciences Corp. shares ...
Exact Sciences (NASDAQ: EXAS) Stock Quote. Follow Insider Trades Visit website. Last Trade: US$64.00 -1.06 -1.63. Volume: 1,800,029. 5-Day Change: -1.75%. YTD ...Nov 4, 2023 · Exact Sciences (NASDAQ:EXAS – Get Free Report) last issued its quarterly earnings results on Tuesday, August 1st. The medical research company reported ($0.45) EPS for the quarter, beating ... Find the latest analyst research for Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Formed in 1995, Exact Sciences ( NASDAQ: EXAS) is a cancer screening and diagnostics company with the aim of early detection and improving cancer treatment. Currently, the company caters to ...Dec 16, 2022 · 11/02/2023 Exact Sciences, a large Cathie Wood holding, came in hot with double-digit sales growth. But EXAS stock reversed lower. 11/02/2023 Exact Sciences, a large Cathie Wood holding, came in ... Exact Sciences Corp. NASDAQ: EXAS is on a self-proclaimed mission to change the way cancer is detected and treated. The Madison, Wisconsin company is among the market's best price performers, advancin...Source: Third-quarter 2023 earnings slides. Currently, EXAS projects its 2023 revenue to be between $2.48 billion and $2.49 billion. Yet, at its current growth pace, my calculations suggest a more ...Exact Sciences Corporation Common Stock ... Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day. Who is on Exact Sciences's Insider Roster? The list of insiders at Exact Sciences includes Brian Baranick, D Scott Coward, Everett Cunningham, Graham Peter Lidgard, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, and Sarah Condella. Learn more on insiders at EXAS.Turning to the calls side of the option chain, the call contract at the $39.00 strike price has a current bid of $3.40. If an investor was to purchase shares of EXAS stock at the current price ...
Exact Sciences (NASDAQ: EXAS) and Guardant Health make diagnostic tests to help screen for cancer. The two healthcare stocks have similar price-to-sales (P/S) ratios, and over the past five years ...
MADISON, Wis., Feb. 7, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS ), a leading provider of cancer screening and diagnostic tests, today announced the launch of the OncoExTra ...
EXAS stock, on the other hand, ended the regular session at 51.92, up 16.4%. ... *Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.Turning to the calls side of the option chain, the call contract at the $51.00 strike price has a current bid of $3.30. If an investor was to purchase shares of EXAS stock at the current price ...EXACT SCIENCES CORP ( EXAS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 77% based on the firm’s underlying fundamentals and the stock’s ...Exact Sciences Corp (NASDAQ:EXAS), a leading global cancer diagnostics company, has recently released its SEC 10-Q filing for the quarter ended September 30, 2023. The company has shown ...Nov 30, 2023 · Exact Sciences Corp EXAS Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating... Exscientia Plc American Depositary Shares (EXAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.See the latest Exact Sciences Corp stock price (EXAS:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Exact Sciences Corp ( NASDAQ:EXAS) is working on the development of additional tests, with the goal of bringing new, innovative cancer tests to patients worldwide. The company has reported a net ...
Exact Sciences was founded in 1995 in Marlborough, Massachusetts, by Stanley Lapidus and Anthony Shuber as a company focused on the development of a non-invasive test for colorectal cancer. The company eventually went public with an initial offering on the NASDAQ in 2001. One company well positioned in this space to benefit from this coming of (middle) age is Exact Sciences ( NASDAQ: EXAS ). The company, founded in the mid-1990s, specializes in diagnostics for ...Analyst Price Forecast Suggests 9.61% Upside. As of April 24, 2023, the average one-year price target for Exact Sciences is 77.82. The forecasts range from a low of 55.55 to a high of $99.75. The ...This year, Exact Sciences (NASDAQ: EXAS) expects its revenue will total just under $2.1 billion. That means that in just five years, its top line will have grown by an incredible 683%.Instagram:https://instagram. aqr managed futuresduhpletaxhighest volume etfs 3 Nov 2023 ... Exact Sciences (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, visits the Nasdaq MarketSite in Times Square.A Look At The Intrinsic Value Of Exact Sciences Corporation (NASDAQ:EXAS) (Simply Wall St.) Jul-10-23 08:21AM Top 5 Non-Tech Nasdaq Winners of 1H With More Upside Left (Zacks) 06:00AM Exact Sciences schedules second quarter 2023 earnings call (PR Newswire) Jul-04-23 10:40AM ... free dividend tracker apptop consumer staples etf Among the largest underlying components of ARKG, in trading today EXACT Sciences Corp. (Symbol: EXAS) is down about 0.3%, Ionis Pharmaceuticals Inc (Symbol: IONS) is up about 3%, and Intellia ... bx stock In the past year, this Zacks Rank #3 (Hold) stock has gained 6.3% against a 9.1% decline of the industry and a 4.7% decline of the S&P 500 composite. The renowned global medical device company has ...Get the latest Exscientia PLC (EXAI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Find the latest press releases from Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.